Bristol Myers Squibb (BMY) Long-Term Debt Repayments (2009 - 2026)

Bristol Myers Squibb (BMY) has 15 years of Long-Term Debt Repayments data on file, last reported at $500.0 million in Q1 2026.

• Long-Term Debt Repayments for Q1 2026 came in at $500.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $11.4 billion (up 298.19% YoY), and the FY2025 annual result was $10.9 billion, up 280.79% from the prior year.
• Long-Term Debt Repayments eased to $500.0 million in Q1 2026 per BMY's latest filing, from $10.1 billion in the prior quarter.
• Over five years, Long-Term Debt Repayments peaked at $10.1 billion in Q4 2025 and troughed at $229.0 million in Q3 2025.
• A 5-year average of $2.5 billion and a median of $1.8 billion in 2023 frame the typical range for Long-Term Debt Repayments.
• The sharpest annual moves came in 2022 and 2023: Long-Term Debt Repayments jumped 457.0% in 2022, then slumped 91.69% in 2023.
• A 5-year view of Long-Term Debt Repayments shows it stood at $2.8 billion in 2022, then slipped by 28.19% to $2.0 billion in 2023, then grew by 23.9% to $2.5 billion in 2024, then surged by 306.3% to $10.1 billion in 2025, then plunged by 95.03% to $500.0 million in 2026.
• Business Quant data shows BMY's Long-Term Debt Repayments at $500.0 million in Q1 2026, $10.1 billion in Q4 2025, and $229.0 million in Q3 2025.